<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068912</url>
  </required_header>
  <id_info>
    <org_study_id>T705aUS204</org_study_id>
    <nct_id>NCT01068912</nct_id>
  </id_info>
  <brief_title>Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Favipiravir in Adult Patients With Uncomplicated Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MDVI, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MDVI, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo-controlled multicenter study evaluating
      the efficacy and safety of two doses of favipiravir in adult patients with uncomplicated
      influenza.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed
      to evaluate the efficacy and safety of a 5-day regimen of favipiravir in influenza patients
      aged 20-80 years. Enrolled patients will be randomly assigned to 1 of 3 parallel treatment
      dose groups:Placebo; Low-dose favipiravir (1000 mg favipiravir BID for 1 day, followed by 400
      mg favipiravir BID for 4 days); High-dose favipiravir (1200 mg favipiravir BID for 1 day,
      followed by 800 mg favipiravir BID for 4 days).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Efficacy of 2 Dose Regimens of Favipiravir Compared With Placebo in Treating Patients With Influenza</measure>
    <time_frame>22 weeks</time_frame>
    <description>Overall time required from first study drug administration to alleviation of the 6 primary influenza symptoms and for temperature (oral) measurements to be less than 38.0°C for patients aged 20 to less than 65 years and less than 37.8°C for patients aged 65 years or older. &quot;Alleviated&quot; was defined as all 6 symptom scores had to be decreased to 1 or below and the decrease remain unchanged for 21.5 hours.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">530</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1: Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose favipiravir regimen: 1000 mg favipiravir twice a day (BID) x 1 day, and 400 mg favipiravir BID x 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days</description>
    <arm_group_label>1: Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days</description>
    <arm_group_label>2: Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Placebo BID x 1 day, and Placebo BID x 4 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who test positive for influenza A or B by a commercially available Rapid
             Antigen Test (RAT) of the nasopharynx. A patient with a negative RAT result may still
             enroll if the sponsor and investigator agree that there is a known influenza outbreak
             circulating in the community.

          2. Patients ≥ 20 but &lt; 65 years of age with a temperature (oral) of 100.4°F (38.0°C) or
             more; patients ≥ 65 years of age with a temperature (oral) of 100.0°F (37.8°C) or more
             at the first visit, or in the 6 hours prior if antipyretics were taken.

          3. Patients with 2 or more of the following symptoms (moderate to severe in intensity) at
             the time of enrollment:

               -  Cough

               -  Sore throat

               -  Headache

               -  Nasal congestion

               -  Feeling feverish

               -  Body aches and pains

               -  Fatigue (tiredness)

        Exclusion Criteria:

          1. Patients who have had influenza symptoms or fever (i.e., one of the symptoms listed
             under the inclusion criteria) for 36 hours or more prior to study screening.

          2. Patients who have underlying chronic respiratory disease (e.g., chronic obstructive
             pulmonary disease [COPD], chronic bronchitis, diffuse panbronchiolitis,
             bronchiectasis, pulmonary emphysema, pulmonary fibrosis, bronchial asthma, or old
             tuberculosis).

          3. Patients who at the beginning of the study are suspected of having bacterial
             respiratory infection (i.e., expectoration of purulent or mucopurulent sputum and/or
             infiltrate in lung in a chest x-ray, etc.).

          4. Patients who have serious chronic diseases. For example, patients with HIV, cancer
             (i.e., requiring chemotherapy within the preceding 6 months), cirrhosis (end-stage),
             and/or unstable renal, cardiac, pulmonary, neurologic, vascular, or endocrinologic
             disease states requiring medication dose adjustments within the last 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Macy Guiont</last_name>
    <role>Study Director</role>
    <affiliation>INC Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>#065</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#156</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#151</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#155</name>
      <address>
        <city>Scottsboro</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#173</name>
      <address>
        <city>Toney</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#161</name>
      <address>
        <city>Tuscumbia</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#089</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#018</name>
      <address>
        <city>Green Valley</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#110</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#105</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#188</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#107</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#019</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#140</name>
      <address>
        <city>Searcy</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#059</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#179</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#032</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#154</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#004</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#144</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#043</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#139</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#096</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#091</name>
      <address>
        <city>Pacific Palisades</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#114</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#111</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#097</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#068</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#035</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#054</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#042</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#197</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#022</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#152</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#060</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#007</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#086</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#016</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#038</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#014</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#052</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#088</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#035</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#094</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#153</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#177</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#012</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#149</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#034</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#040</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#047</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#082</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#166</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#134</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#050</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#163</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#020</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#814</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#080</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#063</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#835</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#804</name>
      <address>
        <city>Fishers</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#803</name>
      <address>
        <city>Franklin</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#198</name>
      <address>
        <city>Greenfield</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#195</name>
      <address>
        <city>Munci</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#168</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#827</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#008</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#138</name>
      <address>
        <city>Shawnee</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#106</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#055</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#823</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#801</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#048</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#085</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#187</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#811</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#015</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#170</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#081</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#017</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#041</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#169</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#112</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#146</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#079</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#176</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#171</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#011</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#164</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#021</name>
      <address>
        <city>Harrisburg</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#178</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#189</name>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#030</name>
      <address>
        <city>Carlisle</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#006</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#182</name>
      <address>
        <city>Grove City</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#083</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#167</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#810</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#071</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#045</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#024</name>
      <address>
        <city>Bridgeville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#815</name>
      <address>
        <city>Clairton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#192</name>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#816</name>
      <address>
        <city>Philladelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#191</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#828</name>
      <address>
        <city>Scottdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#824</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#194</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#819</name>
      <address>
        <city>Clinton</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#805</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#160</name>
      <address>
        <city>Murrells Inlet</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#833</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#831</name>
      <address>
        <city>Pawleys Island</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#147</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#002</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#084</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#001</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#812</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#137</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#037</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#113</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#058</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#066</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#039</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#053</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#132</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#136</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#157</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#158</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#003</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#108</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#180</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#817</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#818</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#830</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#135</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#809</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#822</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#090</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#117</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#832</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#825</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#133</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#142</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#800</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#009</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#172</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#216</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#207</name>
      <address>
        <city>Burwood</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#214</name>
      <address>
        <city>Carlton</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#208</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#205</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#201</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#218</name>
      <address>
        <city>Neutral Bay</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#202</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#204</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#219</name>
      <address>
        <city>Biggera Waters</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#215</name>
      <address>
        <city>Caboolture</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#221</name>
      <address>
        <city>Deception Bay</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#217</name>
      <address>
        <city>Jimboomba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#220</name>
      <address>
        <city>Nerang</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#206</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#223</name>
      <address>
        <city>Mirrabooka</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#222</name>
      <address>
        <city>Morley</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#224</name>
      <address>
        <city>Spearwood</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#613</name>
      <address>
        <city>Antofagasta</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#612</name>
      <address>
        <city>Curico</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#606</name>
      <address>
        <city>Quillota</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#614</name>
      <address>
        <city>Rancagua</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#603</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#607</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#609</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#610</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#602</name>
      <address>
        <city>Talca</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#600</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#601</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#611</name>
      <address>
        <city>Viña del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#306</name>
      <address>
        <city>Otara</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#305</name>
      <address>
        <city>Rotorua</city>
        <state>Bay of Plenty</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#302</name>
      <address>
        <city>Tauranga</city>
        <state>Bay of Plenty</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#301</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#304</name>
      <address>
        <city>Dunedin</city>
        <state>Otago</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#307</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#308</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#702</name>
      <address>
        <city>Florida</city>
        <state>Asuncion</state>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#707</name>
      <address>
        <city>Pai Perez</city>
        <state>Asuncion</state>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#703</name>
      <address>
        <city>esquina Pai Perez</city>
        <state>Asunción</state>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#704</name>
      <address>
        <city>Campos Cervera</city>
        <state>Luque</state>
        <country>Paraguay</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#505</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#511</name>
      <address>
        <city>Callao</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#506</name>
      <address>
        <city>Cusco</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#513</name>
      <address>
        <city>ICA</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#500</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#501</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#502</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#504</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#508</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#509</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#510</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#512</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#515</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#516</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#517</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#514</name>
      <address>
        <city>Piura</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#507</name>
      <address>
        <city>Trujillo</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#421</name>
      <address>
        <city>Benoni</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#402</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#405</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#406</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#408</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#412</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#414</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#404</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#422</name>
      <address>
        <city>Kemptonpark</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#411</name>
      <address>
        <city>Kraaifontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#410</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#407</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#409</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#413</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#415</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#418</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#419</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#420</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#423</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#417</name>
      <address>
        <city>Sandton</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#416</name>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>#401</name>
      <address>
        <city>Soweto</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>New Zealand</country>
    <country>Paraguay</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2010</study_first_posted>
  <results_first_submitted>February 11, 2014</results_first_submitted>
  <results_first_submitted_qc>February 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2014</results_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1: Low Dose Favipiravir</title>
          <description>Favipiravir: 1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days</description>
        </group>
        <group group_id="P2">
          <title>2: High Dose Favipiravir</title>
          <description>Favipiravir: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo comparator: Placebo BID x 1 day, and Placebo BID x 4 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="195"/>
                <participants group_id="P3" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="173"/>
                <participants group_id="P3" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>aggravation influenza</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other underlying illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Population, defined as all patients who received study drug, was used for demographic and baseline characteristics and safety analyses, unless otherwise indicated.</population>
      <group_list>
        <group group_id="B1">
          <title>1: Low Dose Favipiravir</title>
          <description>Favipiravir: 1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days</description>
        </group>
        <group group_id="B2">
          <title>2: High Dose Favipiravir</title>
          <description>Favipiravir: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo comparator: Placebo BID x 1 day, and Placebo BID x 4 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="132"/>
            <count group_id="B2" value="189"/>
            <count group_id="B3" value="197"/>
            <count group_id="B4" value="518"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" lower_limit="20" upper_limit="79"/>
                    <measurement group_id="B2" value="42.6" lower_limit="20" upper_limit="75"/>
                    <measurement group_id="B3" value="42.7" lower_limit="20" upper_limit="80"/>
                    <measurement group_id="B4" value="42.5" lower_limit="20" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mestizo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race, including Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race, excluding Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rapid Antigen Test Result</title>
          <description>Tested positive for influenza A or B by a commercially available rapid antigen test of the nasopharynx. A patient with a negative rapid antigen test result was enrolled if the sponsor and investigator agreed that there was a known influenza outbreak circulating in the community.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type A Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type B positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type A and B positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Virus type identification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>A (H1N1) pdm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A (H3N2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neither</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Efficacy of 2 Dose Regimens of Favipiravir Compared With Placebo in Treating Patients With Influenza</title>
        <description>Overall time required from first study drug administration to alleviation of the 6 primary influenza symptoms and for temperature (oral) measurements to be less than 38.0°C for patients aged 20 to less than 65 years and less than 37.8°C for patients aged 65 years or older. &quot;Alleviated&quot; was defined as all 6 symptom scores had to be decreased to 1 or below and the decrease remain unchanged for 21.5 hours.</description>
        <time_frame>22 weeks</time_frame>
        <population>The primary analysis population for efficacy analyses was the ITTI Population (N=333), defined as all patients who received at least 1 dose of study drug with any available efficacy data after randomization and who tested positive for influenza A or B by PCR assay or culture tests on Day 1 using determinations.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Low Dose Favipiravir</title>
            <description>Favipiravir: 1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days</description>
          </group>
          <group group_id="O2">
            <title>2: High Dose Favipiravir</title>
            <description>Favipiravir:1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo comparator: Placebo BID x 1 day, and Placebo BID x 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Efficacy of 2 Dose Regimens of Favipiravir Compared With Placebo in Treating Patients With Influenza</title>
          <description>Overall time required from first study drug administration to alleviation of the 6 primary influenza symptoms and for temperature (oral) measurements to be less than 38.0°C for patients aged 20 to less than 65 years and less than 37.8°C for patients aged 65 years or older. &quot;Alleviated&quot; was defined as all 6 symptom scores had to be decreased to 1 or below and the decrease remain unchanged for 21.5 hours.</description>
          <population>The primary analysis population for efficacy analyses was the ITTI Population (N=333), defined as all patients who received at least 1 dose of study drug with any available efficacy data after randomization and who tested positive for influenza A or B by PCR assay or culture tests on Day 1 using determinations.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.4" lower_limit="82.4" upper_limit="119.8"/>
                    <measurement group_id="O2" value="86.5" lower_limit="79.2" upper_limit="102.1"/>
                    <measurement group_id="O3" value="91.9" lower_limit="70.3" upper_limit="105.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time required from first study drug administration to alleviation of the 6 primary influenza symptoms and fever. The primary influenza symptoms included cough, sore throat, headache, nasal congestion, body aches and pains, and fatigue. Symptoms were considered alleviated when all were decreased to ≤1 and decrease persisted unchanged ≥ 21.5 hours. Fever was considered alleviated when maintained at &lt; 38.0°C (age 20 to &lt; 65 years) or &lt; 37.8°C (age ≥ 65 years) ≥ 21.5 hours.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <p_value_desc>A step-down approach was applied to the primary analysis, with the higher dose of favipiravir first tested against placebo.</p_value_desc>
            <method>Gehan-Wilcoxon</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1: Low Dose Favipiravir</title>
          <description>Favipiravir: 1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days</description>
        </group>
        <group group_id="E2">
          <title>2: High Dose Favipiravir</title>
          <description>Favipiravir: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo comparator: Placebo BID x 1 day, and Placebo BID x 4 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <description>Patient experienced vulval abscess (CTCAE grade 3) on Day 9 of study. Treated with medication, event resolved 5 days later. Met seriousness criteria of hospitalization. Investigator considered event not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>hepatic encephalopathy</sub_title>
                <description>Patient experienced hepatic encephalopathy (CTCAE grade 1) on Day 4 of study. Treatment not required, event resolved 2 days later. PMH of cirrohsis. Event met seriousness criteria of prolonged hospitalization. Determined as unrelated to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>bronchial obstruction</sub_title>
                <description>Bronchial obstruction (CTCAE grade 1) Day 2 of study (placebo cohort). Withdrawn from study. Treated with medication, event resolved 4 days later. Met serious criteria of hospitalization. Investigator considered event unrelated to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.8</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>tympanic membrane disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>sensitivity of teeth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>ear infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>tonsillits</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>vulval abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>pharyngitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>sinusitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>blood fibrinogen increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>blood uric acid increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>alanine aminotransferase increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>blood triglycerides increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>APTT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>WBC decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>neutrophil count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>gamma-glutamyl transferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>blood phosphorus increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>bilibrubin urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>WBC increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>muscle spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>parasthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>ketonuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>leukocyturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>breast tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>respiratory tract congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>pharyngeal erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>rash erythematous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>hypoaesthesia facial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carol Epstein, Chief Medical Officer</name_or_title>
      <organization>MediVector, Inc., managing member MDVI, LLC</organization>
      <phone>617-439-4500</phone>
      <email>cepstein@medivector.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

